Efficacy and safety of PCSK9 inhibitors for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review and meta-analysis of randomised controlled trials

Imagine your body is a bustling city, and the roads are your blood vessels. To keep traffic flowing smoothly, your body needs a steady supply of fuel, but sometimes it gets a little too much of a specific kind of "traffic jam" material called cholesterol. In most people, the city's cleanup crew works overtime to clear this out. But for some families, there's a glitch in the cleanup crew's instructions. This condition, called heterozygous familial hypercholesterolaemia (HeFH), means the cleanup crew is missing a few workers, so the "traffic jam" material builds up much faster than normal, starting right from childhood. If this buildup isn't stopped, it can clog the roads early, leading to heart trouble much sooner than expected.

To fix this, doctors usually send in the standard cleanup trucks: medicines called statins and ezetimibe. These are like reliable, hardworking trucks that clear a lot of the jam. But sometimes, even with these trucks working hard, the roads are still too crowded. That's when doctors look for a super-charged cleanup crew. Enter the PCSK9 inhibitors. Think of these as a brand-new, high-tech drone fleet that doesn't just pick up the jam; it actually repairs the cleanup crew's instructions so they can work twice as hard. The big question for the medical world was: Do these high-tech drones work safely and effectively on the young drivers of the city (children and teenagers), or are they too powerful for a developing body?

This paper is a massive detective story where researchers gathered all the available evidence to answer that question. They didn't just look at one or two cases; they hunted down every single randomized controlled trial (the gold standard of medical testing) involving three specific types of these new drugs: evolocumab, alirocumab, and inclisiran. They focused strictly on children and teenagers under 18 who had already tried the standard trucks (statins and ezetimibe) but still had high cholesterol levels.

The detectives found three major trials involving 451 young people. The results were pretty clear: the new high-tech drones worked incredibly well at clearing the roads. On average, the drugs lowered the "traffic jam" material (LDL-C) by about 35.44% more than a fake treatment (placebo). In real-world numbers, that's a drop of about 1.63 mmol/L (or 62.93 mg/dL). Even better, nearly two-thirds of the kids taking the real drugs managed to get their levels down to a safe zone (below 130 mg/dL), compared to only about 17% of the kids who got the fake treatment.

But the most important part of the story is the safety check. Parents and doctors were worried: Do these powerful new drugs stunt growth? Do they mess with puberty? The paper found no evidence of that. The kids' height, weight, and development marched right along just like the kids who got the fake treatment. The drugs were also generally well-tolerated. While there were a few more minor "bumps" (like injection site reactions) with the real drugs compared to the fake ones, there was no difference in serious trouble. The only serious side effects mentioned were two cases of fainting, both in one specific group, but the study noted that serious events were rare overall.

However, the authors are careful not to declare a total victory yet. They point out that while the short-term results (up to about a year) look great, we don't have a long-term movie of what happens over decades. We don't know for sure if these drugs will prevent heart attacks later in life, nor do we know if they are worth the high price tag compared to older medicines. The paper concludes that these drugs are a powerful new tool for the kids who still have clogged roads despite the standard trucks, but we need more time and more data to be absolutely sure about the long-term journey.